A Randomized Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics After Different Single-Dose Subcutaneous Treatments of SAR236553/REGN727 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2013
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Adverse reactions
- 28 Feb 2012 Company (Regeneron Pharmaceuticals) added as reported by ClinicalTrials.gov.
- 07 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Oct 2011 New trial record